VALN

Valneva SE

Add to Watchlist

Advanced Chart

10.150

-0.03(-0.295%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.300

Open

9.960

VWAP

10.08

Vol

55.07K

Mkt Cap

824.17M

Low

9.870

Amount

555.37K

EV/EBITDA(TTM)

Total Shares

69.58M

780.09M

EV/OCF(TTM)

P/S(TTM)

3.65

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

3 Analyst Rating

Wall Street analysts forecast VALN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VALN is 15.00 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 10.150

Low

13.00

Averages

15.00

High

18.00

Current: 10.150

Low

13.00

Averages

15.00

High

18.00

Guggenheim

Buy

downgrade

$14 -> $13

2025-09-08

Reason

Guggenheim

Price Target

$14 -> $13

2025-09-08

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Valneva to $13 from $14 and keeps a Buy rating on the shares following the company's recent first half earnings release and the suspension of the Ixchiq BLA in the U.S. Given the suspension, the firm is removing all U.S. Ixchiq sales from its model and also assumes more limited commercial uptake in Europe, but it maintains a Buy rating ahead of the "important" Phase 3 data readout for their Lyme vaccine that it expects by late Q4 or in early Q1 of 2026.

Jefferies

Maury Raycroft

Buy

downgrade

$18 -> $14

2025-08-25

Reason

Jefferies

Maury Raycroft

Price Target

$18 -> $14

2025-08-25

downgrade

Buy

Reason

Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 and keeps a Buy rating on the shares after the FDA suspended the Ixchiq biologics license application based on four new serious adverse events seen outside of the U.S. The firm, which thinks there is some potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure, adds that Ixchiq is "not a major revenue driver" in the near term.

H.C. Wainwright

Brandon Folkes

Buy

maintain

$18

2025-08-25

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$18

2025-08-25

maintain

Buy

Reason

H.C. Wainwright analyst Brandon Folkes reiterates a Buy rating on Valneva after the FDA suspended the license for Ixchiq following four new reports of serious adverse events consistent with chikungunya-like illness. Despite the FDA's decision, Valneva has not revised its revenue guidance for 2025, the analyst tells investors in a research note. The firm points out that management noted Ixchiq represents a relatively small portion of its near-term revenue expectations. The stock selloff today offers an attractive entry for investors who are constructive on a potential positive readout for VLA15 later this year, contends H.C. Wainwright. It views the selloff as overdone and keeps an $18 price target on Valneva.

H.C. Wainwright

Brandon Folkes

initiated

$18

2025-08-19

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$18

2025-08-19

initiated

Reason

H.C. Wainwright analyst Brandon Folkes assumed coverage of Valneva with a Buy rating and $18 price target. The firm says Valneva is a commercial-stage vaccine company with a \"strong proprietary portfolio.\" VLA15 offers a \"de-risked, relatively high-probability path\" to potential blockbuster sales, the analyst tells investors in a research note.

Guggenheim

Vamil Divan

Buy

downgrade

$15 -> $14

2025-05-08

Reason

Guggenheim

Vamil Divan

Price Target

$15 -> $14

2025-05-08

downgrade

Buy

Reason

Guggenheim analyst Vamil Divan lowered the firm's price target on Valneva to $14 from $15 and keeps a Buy rating on the shares. Valneva released detailed Q1 results and provided a corporate update, then announced that the European Medicines Agency is temporarily suspending the use of Valneva's chikungunya vaccine Ixchiq in people over 65 years old as part of the ongoing review of serious adverse events, notes the firm, which is modestly lowering its Ixchiq revenue estimates to account for this new potential safety concern.

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

$17

2025-04-15

Reason

HC Wainwright & Co.

Edward White

Price Target

$17

2025-04-15

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Valneva SE (VALN.O) is -10.25, compared to its 5-year average forward P/E of -227.09. For a more detailed relative valuation and DCF analysis to assess Valneva SE 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-227.09

Current PE

-10.25

Overvalued PE

460.55

Undervalued PE

-914.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.00

Current EV/EBITDA

-22.30

Overvalued EV/EBITDA

53.75

Undervalued EV/EBITDA

-57.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.89

Current PS

3.61

Overvalued PS

5.68

Undervalued PS

2.11

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.7M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

VALN News & Events

Events Timeline

2025-08-25 (ET)

2025-08-25

06:53:04

Valneva reveals U.S. FDA has suspended IXCHIQ's license.

2025-07-29 (ET)

2025-07-29

10:31:41

Valneva signs development, manufacturing agreement with AGC Biologics

2025-06-09 (ET)

2025-06-09

09:27:09

UK restricts use of Valneva chikungunya vaccine for safety review

News

7.0

09-18Globenewswire

VALNEVA UPDATE: Bragar Eagel & Squire, P.C. Launches Investigation into Valneva SE for the Benefit of Stockholders and Urges Investors to Reach Out to the Firm

7.0

09-10Globenewswire

Investor Notice: Pomerantz Law Firm Probes Allegations for Valneva SE Investors - VALN

4.0

09-08Benzinga

Guggenheim Reiterates Buy Rating for Valneva, Adjusts Price Target to $13